Derek DiRocco - 20 Jun 2024 Form 4 Insider Report for Acrivon Therapeutics, Inc. (ACRV)

Reporting relationship: Director
Issuer ticker: ACRV
Reported as of: 20 Jun 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 24 Jun 2024, 17:27:30 UTC
Prior SEC filing: 24 May 2024
Next SEC filing: 05 Feb 2025
Source filing: View source filing
Reporting owner signature: /s/ Rasmus Holm-Jorgensen, Attorney-in-Fact

Key filing fact

Derek DiRocco filed Form 4 for Acrivon Therapeutics, Inc. (ACRV) on 24 Jun 2024.

Key facts

This page summarizes Derek DiRocco's Form 4 filing for Acrivon Therapeutics, Inc. (ACRV).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 24 Jun 2024, 17:27.

Change

Previous filing in this sequence was filed on 24 May 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ACRV transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +20,275
Change %
Price: $0.000000
Shares after: 20,275
Date: 20 Jun 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 20,275
Exercise price: $6.52
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The shares subject to the option shall vest on the date immediately preceding the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through each applicable vesting date.

Footnote F2

Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the stock option for the benefit of RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund and the Nexus Fund II. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying Common Stock.

SEC remarks

Exhibit List: Exhibit 24 - Power of Attorney